BRNS
Barinthus Biotherapeutics plc American Depositary Shares
PHARMACEUTICAL PREPARATIONS
Best Pharmaceutical Stocks 2026 →
Barinthus Biotherapeutics (BRNS) Stock: Buy, Sell, or Hold?
$0.74
-0.02 (-2.49%)
âŧ
5d:
+6.18%
30d:
+23.56%
90d:
+2.79%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (45%)
Quality Score
32/100
Position
FAIR
Forward P/E & Valuation
-0.7x
Next 12M consensus est.
Wall Street Target
$6.00
+710.7% upside
Options IV & Volume
UNKNOWN Vol
UNKNOWN volume confirmation
Support / Resistance
$0.64 / $0.82
Trend: Sideways
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
âšī¸ NEUTRAL: BRNS is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
Get Alerted When BRNS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: BRNS is currently trading at $0.74, which is considered fair based on recent price action.
Technical Outlook: Technically, BRNS is showing sideways momentum. Immediate support is located at $0.64, while resistance sits at $0.82.
Market Sentiment: BRNS scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.00 (+710.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BRNS is showing sideways momentum. Immediate support is located at $0.64, while resistance sits at $0.82.
Market Sentiment: BRNS scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.00 (+710.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Company Quality Score
32/100
(SELL)
Volume Confirmation
UNKNOWN
Confidence Score
44.7%
Trading Range & Key Levels
Support Level
$0.64
Resistance Level
$0.82
Current Trend
Sideways
Technical data as of
Sep 8, 2026
Quantitative Signal Breakdown
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (0/100)
- BULLISH: Trading 710.7% below Wall St target ($6.00)
- WARNING: Composite score 32/100 in the bottom quintile â this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
-0.65
Wall Street Target
$6.00
(+710.7%)
Revenue Growth (YoY)
-100.0%
Share BRNS Analysis
Share this live BRNS analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.
Last updated: November 11, 2026 9:40 PM ET
Data refreshes hourly during market hours. Next update: 10:40 PM
Data refreshes hourly during market hours. Next update: 10:40 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BRNS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
28 analysts |
$91 | 56 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$266 | 55 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 49 HOLD |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$132 | 52 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
22 analysts |
$107 | 33 SELL |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive BRNS Research Pages
